ArticleBMC infectious diseases2025
Trends in antibiotic use in long-term care hospitals during the COVID-19 pandemic: a nationwide cohort study during 2020 and 2023.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Physicians' understanding of antibiotic prescribing in Korean long-term care hospitals: a multicenter cross-sectional study.Journal of health, population, and nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveInformation regarding the use of antibiotics in long-term care hospitals (LCHs) during COVID-19 remains limited. The aim of the study was to examine the antibiotics use in Korean LCHs during the COVID-19 pandemic period.
methodsWe conducted a nationwide cohort study between 2020 and 2023. During this period, a total of 1,835,398 patients were admitted to 1,829 LCHs.
results1,043,346 (56.9%) received antibiotics. The overall antibiotic use in LCHs was 133.33 days of therapy (DOT) per patient-days (PDs), which was lower than that observed in tertiary (933.89), secondary (798.26), and primary care hospitals (566.77). In contrast, the intensity of antibiotic use among treated patients was highest in LCHs (40.01 DOT), exceeding that in tertiary (15.22), secondary (14.60), and primary care hospitals (11.74). Antibiotic use in LCHs steadily rose from 116.18 in January 2020 to 160.65 DOT per 1000 PDs in December 2023, with a notable increase during surge of COVID-19 cases. Segmented regression analysis showed a sustained increase in antibiotic use before the Omicron wave that persisted afterward. Most statistically significant increases were observed in the use of broad-spectrum antibiotics: fourth-generation cephalosporins increased by 348.0%, carbapenems by 114.6%, and glycopeptides by 92.5%.
conclusionsDuring the COVID-19 pandemic, we found a significant increasing trend in antibiotic use, particularly in broad-spectrum antibiotics. These findings highlight the deed for strengthened antibiotic stewardship in LCHs during public health crises. CLINICAL
trial registrationClinical trial number: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.